Legacy Wealth Management LLC MS Sells 3,233 Shares of IQVIA Holdings Inc. $IQV

Legacy Wealth Management LLC MS trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 41.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,519 shares of the medical research company’s stock after selling 3,233 shares during the period. Legacy Wealth Management LLC MS’s holdings in IQVIA were worth $1,215,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of IQVIA during the 3rd quarter valued at about $12,510,000. Vise Technologies Inc. increased its stake in IQVIA by 17.2% during the 3rd quarter. Vise Technologies Inc. now owns 9,601 shares of the medical research company’s stock worth $2,581,000 after purchasing an additional 1,411 shares in the last quarter. Avestar Capital LLC acquired a new stake in IQVIA during the 3rd quarter worth approximately $320,000. Parcion Private Wealth LLC raised its holdings in IQVIA by 13.9% during the 3rd quarter. Parcion Private Wealth LLC now owns 1,312 shares of the medical research company’s stock worth $353,000 after buying an additional 160 shares during the period. Finally, Soltis Investment Advisors LLC bought a new position in IQVIA in the third quarter valued at approximately $461,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Performance

Shares of IQV stock opened at $258.20 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $284.50. The company’s fifty day simple moving average is $266.18 and its 200-day simple moving average is $210.49. The firm has a market cap of $42.55 billion, a PE ratio of 24.10, a P/E/G ratio of 2.45 and a beta of 1.17. The company has a quick ratio of 0.71, a current ratio of 0.83 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The business had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year. Equities research analysts expect that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IQV shares. TD Cowen upped their price target on shares of IQVIA from $288.00 to $307.00 and gave the company a “buy” rating in a report on Thursday. Barclays raised their price objective on shares of IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. HSBC boosted their price objective on shares of IQVIA from $280.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, September 1st. Robert W. Baird increased their target price on IQVIA from $324.00 to $328.00 and gave the stock an “outperform” rating in a report on Tuesday, October 27th. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $294.21.

Insider Buying and Selling at IQVIA

In other news, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.70% of the stock is owned by insiders.

IQVIA Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.